She Faked a Revolution in Blood Testing

Part 1: The Dropout

Elizabeth Holmes grew up in Washington, D.C., the daughter of a Enron executive and a congressional committee staffer. She was ambitious from childhood — her father later recalled her saying she wanted to be a billionaire.

At Stanford, she studied chemical engineering and became fixated on microfluidics — the science of manipulating tiny amounts of fluid. She conceived of a device that could run blood tests on a single drop of blood using miniaturized lab-on-a-chip technology.

In 2003, at 19, she dropped out of Stanford to found Real-Time Cures, later renamed Theranos (a portmanteau of "therapy" and "diagnosis"). Her advisor, Channing Robertson, was so impressed he joined the board. He would remain a supporter long after the fraud was exposed.

Part 2: The Money

Holmes raised money the Silicon Valley way — with a vision, a prototype (which barely worked), and extraordinary charisma. She lowered her voice to a baritone register. She wore exclusively black turtlenecks in conscious imitation of Steve Jobs. She spoke in sweeping, messianic terms about saving lives and democratizing healthcare.

Early investors included Tim Draper (a venture capitalist and family friend), Larry Ellison (co-founder of Oracle), and the Walton family (Walmart heirs). By 2010, Theranos had raised over $400 million.

But there was something unusual about the fundraising: Holmes kept the technology secret. Investors were not allowed to see the Edison device in operation. Due diligence was minimal. The board — packed with political luminaries rather than scientists — provided a stamp of legitimacy that substituted for evidence.

Part 3: The Technology Gap

Inside Theranos, the reality was grim. The Edison — the proprietary device Holmes was promising to the world — could not perform most of the tests Theranos offered.

The fundamental problem was physics. Most blood tests require a certain volume of blood. You can miniaturize the instruments, but you can't miniaturize the biochemistry. A finger prick yields roughly 25-50 microliters of blood. Many standard tests require 100 microliters or more — from a minimum of several drops to full vials.

Theranos's solution was to dilute the sample. But dilution introduces error. And the miniaturized sensors in the Edison were less accurate than full-size commercial analysers.

By 2013, Theranos had begun secretly running most of its tests on modified Siemens analysers — commercial machines that any lab could buy. The Edison was used for only a small fraction of tests. The results from both were often unreliable.

Part 4: The Patients

In 2013, Theranos launched a partnership with Walgreens, opening blood testing centres inside drugstores in Arizona and California. Real patients walked in, had their blood drawn, and received results.

Some of those results were dangerously wrong. Patients were told they had conditions they didn't have. Others received normal results when they were actually sick. The company was performing medical testing on real people with equipment they knew was unreliable.

Part 5: The Culture of Silence

Theranos operated like a cult. Employees were segregated into isolated teams that couldn't communicate with each other. NDAs were aggressive and broad. The legal department, led by Holmes's boyfriend Sunny Balwani, was used as a weapon against internal dissent.

Ian Gibbons, Theranos's chief scientist, had grown increasingly concerned about the technology's limitations. In 2013, he was subpoenaed to testify in a patent lawsuit. According to his wife, he was terrified of being forced to tell the truth about the technology. On the day before his scheduled testimony, Ian Gibbons died by suicide.

Holmes's response, according to multiple accounts, was to send someone to Gibbons's home to try to retrieve Theranos property before his wife returned.

Part 6: The Journalist

John Carreyrou was a two-time Pulitzer Prize-winning reporter at the Wall Street Journal. In early 2015, he received a tip from a former Theranos employee about problems with the technology.

He began investigating. His primary source was Tyler Shultz, a 22-year-old Stanford biology graduate who had worked at Theranos and seen the problems firsthand. Tyler happened to be the grandson of George Shultz — former Secretary of State and Theranos board member.

Tyler had tried to raise concerns with his grandfather. George Shultz sided with Holmes. The family conflict became one of the most painful dimensions of the story.

Part 7: The Investigation

Carreyrou's first article ran on October 16, 2015. It revealed that Theranos was running most of its tests on commercial machines, not the Edison, and that results were unreliable.

Holmes went on an aggressive media counter-offensive. She appeared on television denying everything. Theranos hired David Boies — the lawyer who had argued Bush v. Gore before the Supreme Court — to intimidate sources and threaten the Wall Street Journal.

But the facts were devastating. The FDA had already inspected Theranos and found multiple violations. CMS (Centers for Medicare & Medicaid Services) conducted its own inspection and found conditions that posed "immediate jeopardy to patient health and safety."

In 2016, Theranos voided two years of blood test results — tens of thousands of tests performed on real patients. Walgreens terminated its partnership and later sued for $140 million.

Part 8: The Trial

In June 2018, Elizabeth Holmes and Sunny Balwani were indicted on federal wire fraud charges. The trial, delayed by the pandemic, began in September 2021.

Holmes's defence was extraordinary: she claimed Balwani had been abusive and controlling, that she genuinely believed the technology was on the verge of working, and that exaggeration was normal in Silicon Valley.

In January 2022, the jury found Holmes guilty of four counts of fraud (related to defrauding investors) and not guilty of four counts (related to defrauding patients — a distinction that frustrated many observers). She was sentenced to 11 years and 3 months in federal prison.

Balwani was convicted on all 12 counts against him and sentenced to nearly 13 years.

Part 9: What Theranos Teaches

The Theranos story is a parable about credibility laundering. Holmes didn't convince scientists that her technology worked — she made sure scientists were never in the room. Instead, she surrounded herself with people whose credibility came from politics, military service, and wealth. Their names on the board told potential investors and partners: "This must be legitimate."

It's also a story about the Silicon Valley ethos of "fake it till you make it" colliding with healthcare — a domain where faking it means people get hurt.

And it's a story about how long it takes for the truth to surface when a company has enough lawyers, enough powerful friends, and enough money to keep the walls up.